AbbVie (ABBV)
(Delayed Data from NYSE)
$218.04 USD
-10.16 (-4.45%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $217.73 -0.31 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, AbbVie Inc. has a PEG ratio of 1.44 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.68.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABBV 218.04 -10.16(-4.45%)
Will ABBV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ABBV
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Other News for ABBV
AbbVie (ABBV) Surpasses Q3 Expectations with Strong Revenue Growth
Earnings Scorecard: 24 out of 25 healthcare firms deliver EPS wins this week
Dividend Champion, Contender, And Challenger Highlights: Week Of November 2
What You Missed On Wall Street On Friday
ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November